Top 5 Companies Leading the Global Neuroendocrine Tumours Treatment Market

Pfizer Inc, Novartis AG, Ipsen Pharma, Abbvie Inc, and AVEO Pharmaceuticals, Inc, among others, are key players in the global neuroendocrine tumours treatment market. 

The global neuroendocrine tumours treatment market would likely grow at a CAGR of 10.1% during 2022-2027. The market is likely to be driven by the increasing number of patients with neuroendocrine tumours (generally with metastatic disease, and warranting systemic therapy) across the globe. Leading companies are engaged in developing innovative solutions for the treatment of neuroendocrine tumours. Such developments are likely to boost the global neuroendocrine tumours treatment market. Asia, North America and Europe are likely to be key markets.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Top 5 Companies in the Global Neuroendocrine Tumours Treatment Market

Pfizer Inc

Pfizer Inc is a renowned international research-based pharmaceutical and biomedical company engaged in the development, discovery, production and marketing of prescription drugs for animals and humans. The company seeks to utilize science and its global resources to deliver innovative therapies towards extending and significantly enhancing lives; it works across developing and developed markets to advance prevention, wellness, treatments and cures to complex and feared illnesses. 

Novartis AG

Novartis AG is a leading international medicines company that aims to reimagine medicine and enhance the lives of individuals. The company uses innovative science and digital technologies to develop transformative treatments in domains of great medical need. Novartis products are used by approximately 1 billion people every year; the company employs nearly 125 000 people across the globe. Specialties include Innovation, Research, Sustainability, Quality, Generic Medicines and Biosimilars, Innovative Medicine, Eye Care, Cell and Gene Therapy, and Data and Digital.

Ipsen Pharma

Ipsen Pharma is an international specialty-driven biopharmaceutical group that focuses on innovation and specialty care. The company develops and markets innovative medications in three major therapeutic domains - Oncology, Neuroscience and Rare Disease. Ipsen is committed to oncology; this is clear by the company’s expanding portfolio of major therapies for neuroendocrine tumours, prostate cancer, pancreatic cancer, and renal cell carcinoma. Ipsen also has an established consumer healthcare business. The company sells over twenty drugs in more than 115 nations, and has direct commercial presence in over thirty countries. Specialties include Primary Care, Specialty Care (oncology, neuroscience, endocrinology), Pharmaceuticals, and Research (peptides, toxins). 

Abbvie Inc

Abbvie Inc seeks to develop and deliver innovative medications aimed at solving serious health problems and challenges. The company seeks to have a significant influence on individuals’ lives across many major therapeutic areas such as oncology, immunology, eye care, neuroscience, women’s health, virology, and gastroenterology, in addition to services and products across the company’s Allergan Aesthetics portfolio. Specialties include Biotechnology, Biopharmaceutical, Research and Development, Innovation, Biotherapeutics, Manufacturing, Immunology, Oncology, Neuroscience, Virology, and Women’s Health.

AVEO Pharmaceuticals

AVEO Pharmaceuticals is a commercial-stage, oncology-oriented biopharmaceutical company that seeks to deliver medications offering a better life for individuals with cancer. AVEO markets FOTIVDA® (tivozanib) in USA for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) after two or more prior systemic therapies.